COSMNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Cosmos Health Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026
$0.33−0.01 (-1.90%)
Close on Oct 19, 2026
- Market cap
- $19.48M
- P/E (TTM)
- –
- Dividend yield
- –
Cosmos Health Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Wholesale [Member] | $59.32M | $51.59M | $50.74M | – | – | – | – | 90.9% | +15.0% |
| Nutraceuticals and Pharmaceuticals [Member] | $4.26M | $1.97M | $2.29M | – | – | – | – | 6.5% | +116.7% |
| Pharma manufacturing [Member] | $1.69M | $865.37K | $344.71K | – | – | – | – | 2.6% | +95.2% |
| Other [Member] | $1.23K | $0 | $0 | – | – | – | – | 0.0% | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Cosmos Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.